Kornimate/medical-research-clean huggingface dataset:
the correlation characteristics between mental health and gut microbiota of college students in qingyuan vocational education city

Conditions: Depression; Anxiety

Summary: the goal of this observational study is to learn about the mental health status and gut microbiota characteristics of college students in qingyuan vocational education city. the main question it aims to answer is: how is the mental condition of college students in qingyuan vocational education city? is there a correlation between the mental condition and the microbial characteristics of college students in qingyuan vocational education city? participants will answer online survey questions about their demographic characteristics, disease history, gastrointestinal status, lifestyle habits, and psychological health information. 200 participants from each of the following groups will be included: healthy individuals, anxious individuals and depressive individuals. fecal samples will be collected for microbiome testing and analysis to obtain their microbial characteristics and to analyze the impact of mental health status on microbial changes.


Eligibility criteria:
inclusion criteria: healthy individuals: 1. ages 18 to 25 years old. 2. resident in the local area for more than one month. 3. no obvious signs or symptoms of disease. 4. good psychological condition. 5. college students currently enrolled in qingyuan vocational education city. 6. having signed an informed consent form, willing to provide relevant survey information and fecal samples. anxious individuals: 1. ages 18 to 25 years old. 2. resident in the local area for more than one month. 3. self-rating anxiety scale score greater than or equal to 50. 4. college students currently enrolled in qingyuan vocational education city. 5. having signed an informed consent form, willing to provide relevant survey information and fecal samples. depressive individuals: 1. ages 18 to 25 years old. 2. resident in the local area for more than one month. 3. self-rating depression scale score greater than or equal to 53. 4. college students currently enrolled in qingyuan vocational education city. 5. having signed an informed consent form, willing to provide relevant survey information and fecal samples. exclusion criteria: 1.pregnant and lactating women.
coadministration of ezetimibe and atorvastatin in patients with primary hypercholesterolemia (p05456)

Conditions: Hypercholesterolemia

Summary: evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in participants with hypercholesterolemia who have not reached low density lipoprotein (ldl)-cholesterol target with 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitors.


Eligibility criteria:
inclusion criteria: * participants with hypercholesterolemia who satisfy the following criteria: * participants who have used any of the following 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitors (hereinafter referred to as "statins") for 4 weeks or longer before the start of the observation period and whose low density lipoprotein (ldl)-cholesterol level during the treatment had not reached lipid management target * age: 20 years of age or older (at the time of obtaining informed consent) * sex: both males and females * inpatient/outpatient: out-patient exclusion criteria: * participants for whom any of the following is applicable: * participants whose fasted triglyceride level measured at the start of the observation period or the treatment period exceeds 500 mg/dl * participants with homozygous familial hypercholesterolemia * participants with creatine phosphokinase (cpk) \> 2x upper limit of normal (uln) measured at the start of the observation period or the treatment period. * participants with serious hepatic disorder, or participants with alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 2x uln measured at the start of the observation period or the treatment period. * participants with a history of hypersensitivity to any ingredient of ezetimibe tablets or atorvastatin tablets * pregnant, nursing women, women who may be pregnant, or participants wishing to be pregnant during the study. * participants who have discontinued use of serum lipid lowering agents for less than 4 weeks at the start of the treatment period (8 weeks in the case of probucol). (however, if the participant had taken a serum lipid lowering agent before the test conducted at the start of the observation period, a period of discontinuation of 27 days, or 55 days in the case of probucol, is allowed.) * participants who are using cyclosporine from after the start of the observation period * participants with a history of ezetimibe use * participants with hyperlipidemia associated with the following diseases: * hypothyroidism * obstructive gall bladder or biliary disease * chronic renal failure * pancreatitis * participants with hyperlipidemia associated with concomitant use of drugs having adverse effect on serum lipids, etc * participants who have received an investigational drug within 4 weeks of the start of the observation period * other participants deemed not appropriate for study entry by the investigator
evaluate the efficacy of oxybutynin chloride in patients with primary hyperhidrosis

Conditions: Hyperhidrosis

Summary: treatment of primary hyperhidrosis through a comparative study between oxybutynin hydrochloride and placebo. hydrochloride may decrease the symptoms of hyperhidrosis improving the subject's quality of life.

clinical trial phase iii, randomized, national, prospective, double-blind, multicenter, comparative between oxybutynin hydrochloride and placebo, to be held in participants aged over 18 years to evaluate the therapeutic efficacy and safety of oxybutynin chloride to systemic treatment of primary hyperhidrosis. primary hyperhidrosis is a relatively common disorder, affecting approximately 3% of the population. it affects both sexes similarly and in all age groups, varying only the starting age of symptoms according to the most affected part of the body: childhood - plantar and palmar hyperhidrosis adolescence - axillary hyperhidrosis adult - craniofacial hyperhidrosis there is a family history associated with between 12.5% and 56.5% of the participants, according to epidemiological studies. initially the subjects will be evaluated on the inclusion and exclusion criteria through screening and safety tests such as blood tests , ecg and tonometry, to confirm enrollment. when included will be randomized into the corresponding study arm to start study treatment. during the period of the study it will evaluate the efficacy parameters of the drug. the treatment for each subject will be about 8 weeks. the inclusion period is foreseen for 6 months and may be extended or decreased according to the pace of inclusion. the data are summarized according to the study group (per dose and per visit, if applicable) through appropriate descriptive statistics to the variable type. frequency and percentage will be used for the variables. the adverse events (ae) will be analyzed based on questioning by the investigators in relation to the ae experienced by the subjects. the orientation will be to the subject to note the symptom, the date and time that the event appeared.

Eligibility criteria:
inclusion criteria: * understanding, agreement and consent form signed; * literate; * confirmed diagnosis for primary hyperhidrosis; * screening tests at normal standards; * absence of pregnancy by beta-human chorionic gonadotropin test; exclusion criteria: * secondary hyperhidrosis; * myasthenia gravis; * lactation; * hypersensitivity to oxybutynin; * use more than 500mg of caffeine; * alcoholism; * use of illicit drug; * changes in ecg (echocardiogram) or tonometry; * any clinical condition that the investigator considers clinically significant.

Keywords: hyperhidrosis oxybutynin
a phase 2 clinical study to investigate effects of darapladib in subjects with diabetic macular edema

Conditions: Retinopathy, Diabetic

Summary: the purpose of this study is to characterize the systemic and ocular safety and tolerability, pharmacokinetics, exploratory efficacy and pharmacodynamics of 3 months of repeat administration of oral darapladib in diabetic macular edema patients with centre involvement.

this is a multi-national, multi-centre, randomised, double-masked, placebo-controlled, parallel-group study of repeat oral administration of 160 mg darapladib for 3 months in adult subjects with dme with centre involvement. eligible subjects will be randomised in a 2:1 ratio of active treatment to placebo, with the placebo group to allow a comparison of safety between treatment arms and to minimize the open label effect that can be observed with the visual acuity endpoint. the primary aim of the study is to determine the effect of repeat doses of darapladib on the mean change from baseline of both best-corrected visual acuity (bcva) and spectral domain oct (sd-oct) centre subfield. the study eye will be examined for changes over the life of the study. as this investigational treatment is systemic, the fellow eye may be examined in tandem to provide additional data.

Eligibility criteria:
inclusion criteria: * a female subject is eligible to participate if she is of: non-childbearing potential or child-bearing potential and agrees to contraception for an appropriate period of time * diagnosis of diabetes mellitus (type 1 or type 2) * confirmation of dme in the study eye by angiography * confirmation of retinal thickening in the study eye by study doctor * best corrected visual acuity score of 78-24 letters in the study eye exclusion criteria: * additional eye disease in the study eye that could compromise study assessments * intraocular surgery, or laser photocoagulation in the study eye within 3 months of dosing * uncontrolled intraocular pressure in the study eye despite treatment with glaucoma medication * uncontrolled diabetes * certain types of liver disease * severe reduction in kidney function or removal of a kidney or kidney transplant * blood pressure higher than normal despite lifestyle changes and treatment with medications * certain medications that may interfere with the study medication or eye assessments (these will be identified by the study doctor) * current severe heart failure * severe asthma that is poorly controlled with medication * previous severe allergic reaction to food, medications, drink, insect stings, etc * if both birth parents are at least 50% japanese, chinese, or korean ancestry, must have a blood sample collected for lp-pla2 activity. those with lp-pla2 activity less than or equal to 20.0 nmol/min/ml are excluded * recent participation in a study of an investigational medication * any other reason the investigator deems the subject should not participate in the study * other protocol-defined inclusion/exclusion criteria may apply

Keywords: diabetic macular edema
a study of tirzepatide (ly3298176) compared with placebo in adults with type 1 diabetes and obesity or overweight

Conditions: Type 1 Diabetes; Obesity; Overweight

Summary: the main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. participation in the study will last about 49 weeks.


Eligibility criteria:
inclusion criteria: * have type 1 diabetes and on insulin treatment for at least one year prior to screening * have an hba1c value of 7.0% to 10.5% inclusive, at screening * have a body mass index (bmi) of ≥25 kilograms per square meter (kg/m2) at screening * are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study exclusion criteria: * have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (dka)) during the period of 180 days prior to screening and until randomization. * have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * have had chronic or acute pancreatitis * have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
assement of the morphological characteristics of the hips and correlating them with the pathology found

Conditions: Hip Pain Chronic; Musculoskeletal Disease; Femoral Anteversion

Summary: the investigators' objective is the anatomical analysis of hips studied through mri, assessing their morphological characteristics and correlating them with the pathology found. a retrospective search was performed using a database of consecutive reports of 137 adults pelvis mri examinations obtained at mri center in zaragoza. in all the images the investigators are going to measure the ischiofemoral space, quadratus femoris space, cervicodiaphysal angle and femoral version angle. the investigators evaluated different qualitative changes in the signal intensity of the quadratus femoris muscle as normal, edema, fatty infiltration or atrophy, and of the gluteus muscles as tendinopathy or atrophy, too.

the investigators' objective is the anatomical analysis of hips studied through mri, assessing their morphological characteristics and correlating them with the pathology found. a retrospective search was performed using a database of consecutive reports of 137 adults pelvis mri examinations obtained at mri center in zaragoza. the investigators create a protocol for a retrospective review study, with the aim of analysis all the recorded mri findings during this time. the criteria for patient inclusion were: age \> 18 years old, who had realised a pelvis mri for any cause at mri center. exclusion criteria included age \< 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture. in all the images the investigators are going to measure the ischiofemoral space, quadratus femoris space, cervicodiaphysal angle and femoral version angle. the investigators evaluated different qualitative changes in the signal intensity of the quadratus femoris muscle as normal, edema, fatty infiltration or atrophy, and of the gluteus muscles as tendinopathy or atrophy, too.

Eligibility criteria:
inclusion criteria: * age \> 18 years old exclusion criteria: * age \< 18 years old * inadequate imaging quality * medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
sentinel lymph node technique in multifocal breast cancer

Conditions: Breast Cancer

Summary: the scope of this trial is to assess the sentinel lymph node technique in multifocal breast cancer

the sentinel lymph node is located preferentially by: * association of subareolar injection of technecium and blue dye * or, in case of blue dye allergy, by the subareolar injection of technecium only * or, in case of no possibility of radioactive isotope subareolar injection , by blue dye injection only this procedures are made the day before the surgery or the day of the surgery * this procedure is immediately follows by complete axillary dissection during breast surgery * the anatomopathologic analysis of the 2 samples (sentinel lymph node and axillary dissection) and the histologic confirmation on the removed tumor of the multifocal nature of the breast cancer correspond to the end of the study for the patient.

Eligibility criteria:
inclusion criteria: * multifocal invasive breast cancer * at least 2 focuses (clinically and/or by mammography or ultrasound) * proven by pre-surgical histology (on 1 focus at least) * age \> 18 years old * clinically negative axillary lymph nodes * no treatment before surgery * signature of written informed consent exclusion criteria: * multifocality proven after surgery * non invasive breast cancer * inflammatory breast cancer * axillary lymph node * metastatic disease * previous homolateral breast cancer * dementia or alterated mental status * pregnant or lactating woman

Keywords: adenocarcinoma, breast, multifocal lesions, surgery
assessment of the impact of clinical pharmacogenomics on real and potential medication use in veterans

Conditions: Pharmacogenetics; Depressive Disorder, Major; Medication Therapy Management

Summary: the purpose of this study is to assess the prevalence of veterans with major depressive disorder (mdd) who are being treated with a medication that has current clinical pharmacogenetics implementation consortium (cpic) or pharmacogenomics knowledgebase (pharmgkb) actionable recommendations that have a pharmacogenomic variation that impacts the safety or efficacy of the subject medication.


Eligibility criteria:
inclusion criteria: 1. age ≥ 19 years 2. prescribed at least one chronic medication for mental health which is considered pharmacogenomically actionable, as defined above (amitriptyline, doxepin, imipramine, nortriptyline, citalopram, escitalopram, fluvoxamine, paroxetine, sertraline, or venlafaxine). 3. diagnosis of major depressive disorder (mdd) exclusion criteria: 1. subject is a prisoner or is under a court order for treatment as part of a sentence or incarceration 2. persistent medication non-adherence for reasons not potentially linked to pharmacogenomic variation (e.g. inability to obtain medications due to cost; non-adherence due to cognitive impairment) 3. individuals receiving mental health treatment/care from a non-va facility 4. individuals who are terminally ill 5. inability to communicate in and/or understand english
stroke-like migraine attacks after radiation treatment (smart) syndrome language intervention

Conditions: Migraine Disorders; Aphasia

Summary: stroke-like migraine attacks after radiation therapy-also known as smart syndrome-constitute a rare condition typically characterized by headache, seizures, vision abnormalities, hemiparesis, and aphasia. the condition usually resolves within a few days or weeks of onset with no residual impairments. however, resolution in some cases extends over a period of months rather than weeks and may be incomplete. the purpose of this case report is to provide an in-depth description of the progression of changes in cognitive and language functioning for a person exhibiting smart syndrome characterized by slow recovery.


Eligibility criteria:
inclusion criteria: * exhibit cognitive and language deficits secondary to smart syndrome * be a former or current client of quality living, inc., omaha, nebraska * be a native speaker of english exclusion criteria: -

Keywords: cognitive impairment
implementation of hysteroscopy in flanders and the netherlands

Conditions: Hysteroscopy; Minimally Invasive Surgical Procedures; Polyp; Myoma; Uterine Septum; Placental Remnant; Adhesiolysis

Summary: by means of a questionnaire the investigators will study the implementation of hysteroscopy in flanders and the netherlands

hysteroscopy is a minimally invasive method for diagnosis and treatment of intra-uterine abnormalities. complication and failure rates are low because of the direct visualisation of the treated abnormality. moreover, hysteroscopic procedures replaced 'blind' (curettage) and more invasive interventions (hysterectomy). the field of hysteroscopy has developed over the years. changes occurred in hysteroscopic instruments and in the use of energy sources. an important development is the smaller diameter of the hysteroscopic system which makes it suitable for an outpatient setting. not every gynaecologist, however, has the appropriate hysteroscopic skills or setting to carry out these procedures. the incorporation of hysteroscopic procedures into daily practice in flanders is unclear. in the netherlands 2 surveys were conducted in the past to question the treatment options for polypectomy in an outpatient setting on the one hand and the diffusion of hysteroscopy on the other hand. the investigators want to study the diffusion of hysteroscopy in flanders and the netherlands. moreover the investigators want to provide an overview of the hysteroscopic procedures implemented, as well as the setting they are performed in. an electronic questionnaire (limeservice) will be sent to all gynaecologists in flanders and the netherlands. participation is voluntary and anonymous. after informed consent all gynaecologists are asked to complete the first part of the questionnaire containing general information. the second part is specific for gynaecologists performing hysteroscopy themselves, and inquires about the procedures they carry out.

Eligibility criteria:
inclusion criteria: * gynaecologist exclusion criteria: * residents in training for gynaecology/obstetrics

Keywords: hysteroscopy diffusion implementation diagnostic hysteroscopy operative hysteroscopy
evaluating deep breathing in health participants using a device called impulse oscillometry

Conditions: Breathing, Mouth; Lung Function Decreased

Summary: this study will determine if resistance of the airway to airflow and pressure, measured by impulse oscillometry, is impacted by a deep breathe maneuver in a small cohort of healthy human subjects.


Eligibility criteria:
inclusion criteria: * vaccinated against covid-19 * ability to provide informed consent * willingness to perform breathing test * willingness to provide basic demographic data * must be able to speak and understand english exclusion criteria: * unable to or unwilling to provide consent, perform test, or provide basic demographic data
comparison of surgical outcomes of craniotomy and craniectomy in posterior fossa lesions

Conditions: Posterior Fossa Lesion

Summary: the purpose of this randomized controlled trial is to compare the surgical outcomes of craniotomy and craniectomy among patients with posterior fossa lesions. the study aims to determine differences in post-operative complications, hospital stay duration, and patient recovery between the two surgical techniques.

patients diagnosed with posterior fossa lesions will be randomly assigned into two groups. group a will undergo craniotomy, where the bone flap is replaced after dural closure, while group b will undergo craniectomy, where the bone is permanently removed. outcomes will be assessed based on post-operative complications such as csf leakage, pseudomeningocele formation, post-operative headache, and length of hospital stay. the study aims to provide evidence to determine the superior surgical approach in terms of patient outcomes and healthcare cost reduction.

Eligibility criteria:
inclusion criteria: * patients diagnosed with posterior fossa lesions * age range: 7-70 years * patients with cerebellar hematoma (traumatic or spontaneous) exclusion criteria: * previous posterior fossa surgery * brainstem hematoma * tumors involving the overlying dura or bone

Keywords: craniotomy craniectomy neurosurgery posterior fossa brain tumors